Literature DB >> 7791538

Endotoxin inactivating action of plasma in patients with liver cirrhosis.

H Fukui1, S Tsujita, M Matsumoto, M Morimura, H Kitano, K Kinoshita, E Kikuchi, Y Okamoto, T Tsujii.   

Abstract

The endotoxin inactivating action of plasma was evaluated in 62 patients with cirrhosis and 10 healthy subjects. Endotoxin from E. coli 0111:B4 was added to each plasma sample to a final concentration of 250 pg/ml and the percentage loss of endotoxin activity by incubation (37 degrees C for 1 h) was calculated as the endotoxin inactivating rate. The plasma endotoxin inactivating rate in cirrhotics was significantly greater than that in healthy subjects, although patients with Child C cirrhosis and marked hyperbilirubinemia had a significantly lower endotoxin inactivating rate than other cirrhotics. The plasma endotoxin inactivating rate was positively correlated to serum HDL-cholesterol levels. In patients with Child A and Child B cirrhosis, the endotoxin inactivating rate was positively correlated to the endotoxin binding capacity of plasma albumin. The present results support the assumption that the plasma of cirrhotics has a high endotoxin inactivating capacity. Its decrease may augment endotoxicity in patients with advanced liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7791538     DOI: 10.1111/j.1600-0676.1995.tb00115.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  7 in total

Review 1.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

2.  Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Varun Chandrashekaran; Firas Al Hasson; Udai P Singh; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Eur J Pharmacol       Date:  2018-09-05       Impact factor: 4.432

Review 3.  Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance.

Authors:  Graziella Privitera; Luisa Spadaro; Simona Marchisello; Giuseppe Fede; Francesco Purrello
Journal:  Dig Dis Sci       Date:  2017-11-25       Impact factor: 3.199

Review 4.  Innate immune dysfunction in acute and chronic liver disease.

Authors:  Bettina Leber; Ursula Mayrhauser; Michael Rybczynski; Vanessa Stadlbauer
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 5.  Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?

Authors:  Hiroshi Fukui
Journal:  Inflamm Intest Dis       Date:  2016-07-20

6.  Association between serum albumin and cognitive dysfunction in hepatic encephalopathy: An exploratory data analysis.

Authors:  Kosuke Kaji; Kiwamu Okita; Kazuyuki Suzuki; Ikuya Sato; Masaki Fujisawa; Hitoshi Yoshiji
Journal:  JGH Open       Date:  2020-12-07

Review 7.  Gut Microbiota and Host Reaction in Liver Diseases.

Authors:  Hiroshi Fukui
Journal:  Microorganisms       Date:  2015-10-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.